Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 7/20 | 0.69 |
| ▸ | CASP7 | P55210 | 3/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.69 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.69 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.69 |
| ▸ | TP53 | P04637 | 2/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.69 |
| ▸ | BLM | P54132 | 2/20 | 0.69 |
| ▸ | VDR | P11473 | 2/20 | 0.69 |
| ▸ | USP2 | O75604 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.69 |
| ▸ | TSHR | P16473 | 2/20 | 0.69 |
| ▸ | MDM4 | O15151 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.69 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.69 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.69 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Stigmastanol SCHEMBL14404969 | 1.00 | GPBAR1 (0.69) | GPBAR1CASP7TDP1HIF1AEPHA2 | |
| Stigmastanol SCHEMBL13324290 | 1.00 | GPBAR1 (0.69) | GPBAR1CASP7TDP1HIF1AEPHA2 | |
| Stigmastanol SCHEMBL18508099 | 1.00 | GPBAR1 (0.69) | GPBAR1CASP7TDP1HIF1AEPHA2 | |
| Stigmastanol SCHEMBL3149663 | 1.00 | GPBAR1 (0.69) | GPBAR1CASP7TDP1HIF1AEPHA2 | |
| Stigmastanol SCHEMBL133726 | 1.00 | GPBAR1 (0.69) | GPBAR1CASP7TDP1HIF1AEPHA2 | |
| Stigmastanol SCHEMBL18508083 | 1.00 | GPBAR1 (0.69) | GPBAR1CASP7TDP1HIF1AEPHA2 | |
| Stigmastanol SCHEMBL18934457 | 1.00 | GPBAR1 (0.69) | GPBAR1CASP7TDP1HIF1AEPHA2 | |
| Stigmastanol SCHEMBL12429027 | 1.00 | GPBAR1 (0.69) | GPBAR1CASP7TDP1HIF1AEPHA2 | |
| Stigmastanol SCHEMBL21927840 | 1.00 | GPBAR1 (0.69) | GPBAR1CASP7TDP1HIF1AEPHA2 | |
| Stigmastanol SCHEMBL30148100 | 1.00 | GPBAR1 (0.69) | GPBAR1CASP7TDP1HIF1AEPHA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1565191-A1 | DELIVERY COMPOSITION AND METHOD | NOVAVAX, INC. (US) | 2005-08-24 | — | — | EP | claimed |
| WO-2004041287-A1 | DELIVERY COMPOSITION AND METHOD | NOVAVAX, INC. (US) | 2004-05-21 | — | — | WO | claimed |
| US-20040087564-A1 | Delivery composition and method | NOVAVAX, INC. | 2004-05-06 | — | — | US | claimed |
| US-7691834-B2 | Substance for lowering high cholesterol level in serum and methods for preparing and using the same | RAISIO NUTRITION LTD. (FI) | 2010-04-06 | — | — | US | disclosed |
| EP-0594612-B2 | Process for the preparation of a substance comprising a beta-sitostanol fatty acid ester or a mixture thereof | RAISIO NUTRITION LTD (FI) | 2010-02-24 | — | — | EP | disclosed |
| US-20070231447-A1 | STEROL COMPOSITIONS AND METHODS OF MAKING SAME | ARCHER-DANIELS-MIDLAND COMPANY (US) | 2007-10-04 | — | — | US | disclosed |
| US-20070042102-A1 | Methods of forming phytosterol-fortified cocoa powder and the product formed therefrom | ARCHER -DANIELS- MIDLAND COMPANY | 2007-02-22 | — | — | US | disclosed |
| EP-1632137-A1 | Compositions and processes for water-dispersible phytosterols and phytostanols | Kraft Foods Holdings, Inc. (US) | 2006-03-08 | — | — | EP | disclosed |
| US-7002030-B2 | Substance for lowering high cholesterol level in serum and methods for preparing and using the same | RAISIO BENECOL LTD. (FI) | 2006-02-21 | — | — | US | disclosed |
| US-20050272711-A1 | Substance for lowering high cholesterol level in serum and methods for preparing and using the same | RAISIO BENECOL LTD. | 2005-12-08 | — | — | US | disclosed |
| EP-1565191-A1 | DELIVERY COMPOSITION AND METHOD | NOVAVAX, INC. (US) | 2005-08-24 | — | — | EP | disclosed |
| US-6174560-B1 | Substance for lowering high cholesterol level in serum and methods for preparing and using the same | RAISIO BENECOL, LTD. (FI) | 2001-01-16 | — | — | US | disclosed |
| WO-2000061694-A1 | METHOD FOR MANUFACTURING FAT-SOLUBLE PHYTOSTEROL OR PHYTOSTANOL ESTER OF UNSATURATED FATTY ACID | EUGENE SCIENCE, INC. (KR) | 2000-10-19 | — | — | WO | disclosed |
| EP-1003388-A1 | PRODUCT, METHOD FOR ITS MANUFACTURE, AND ITS USE | Danisco Finland OY (FI) | 2000-05-31 | — | — | EP | disclosed |
| US-5958913-A | ADMINISTERING SATURATED STEROL FATTY ACID ESTER | RAISIO BENECOL LTD. (FI) | 1999-09-28 | — | — | US | disclosed |
| WO-1998058554-A1 | PRODUCT, METHOD FOR ITS MANUFACTURE, AND ITS USE | DANISCO FINLAND OY (FI) | 1998-12-30 | — | — | WO | disclosed |
| EP-0594612-B1 | A SUBSTANCE FOR LOWERING HIGH CHOLESTEROL LEVEL IN SERUM AND A METHOD FOR PREPARING THE SAME | RAISION TEHTAAT OY AB (FI) | 1997-08-06 | — | — | EP | disclosed |
| US-5502045-A | REDUCING ABSORPTION OF CHOLESTEROL IN BLOOD USING SITOSTANOL FATTY ESTER | RAISION TEHTAAT OY AB (FI) | 1996-03-26 | — | — | US | disclosed |
| EP-0594612-A1 | A SUBSTANCE FOR LOWERING HIGH CHOLESTEROL LEVEL IN SERUM AND A METHOD FOR PREPARING THE SAME. | RAISION MARGARIINI OY (FI) | 1994-05-04 | — | — | EP | disclosed |
| WO-1992019640-A1 | A SUBSTANCE FOR LOWERING HIGH CHOLESTEROL LEVEL IN SERUM AND A METHOD FOR PREPARING THE SAME | RAISION MARGARIINI OY (FI) | 1992-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087564-A1 | Delivery composition and method | LDLR, ANXA2, SGMS2 | GPBAR1 193/4885CASP7 1725/4885TDP1 4353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.